R. Descourt

1.5k total citations
80 papers, 522 citations indexed

About

R. Descourt is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, R. Descourt has authored 80 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Pulmonary and Respiratory Medicine, 58 papers in Oncology and 8 papers in Surgery. Recurrent topics in R. Descourt's work include Lung Cancer Treatments and Mutations (47 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Lung Cancer Research Studies (23 papers). R. Descourt is often cited by papers focused on Lung Cancer Treatments and Mutations (47 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Lung Cancer Research Studies (23 papers). R. Descourt collaborates with scholars based in France, United States and Réunion. R. Descourt's co-authors include Gilles Quéré, C. Chouaïd, G. Robinet, J.B. Auliac, Margaux Geier, R. Corre, I. Monnet, R. Lamy, Florian Guisier and Claire Joly and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

R. Descourt

73 papers receiving 518 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Descourt France 13 364 345 78 62 58 80 522
Ofer Rotem Israel 11 379 1.0× 312 0.9× 113 1.4× 99 1.6× 72 1.2× 30 516
Angélique Da Silva France 7 451 1.2× 176 0.5× 51 0.7× 30 0.5× 46 0.8× 19 580
Takatoshi Fujishita Japan 13 554 1.5× 370 1.1× 99 1.3× 103 1.7× 57 1.0× 32 793
Farastuk Bozorgmehr Germany 16 483 1.3× 466 1.4× 122 1.6× 92 1.5× 137 2.4× 63 748
Laurence Venat‐Bouvet France 14 366 1.0× 138 0.4× 96 1.2× 181 2.9× 23 0.4× 40 647
Anne‐Flore Plane France 6 479 1.3× 168 0.5× 63 0.8× 20 0.3× 45 0.8× 13 656
Xiaobo He China 7 412 1.1× 215 0.6× 79 1.0× 166 2.7× 51 0.9× 8 561
Atsuto Mouri Japan 16 520 1.4× 385 1.1× 51 0.7× 43 0.7× 58 1.0× 72 677
Marie Florescu Canada 12 188 0.5× 240 0.7× 45 0.6× 33 0.5× 17 0.3× 43 367
Shota Omori Japan 20 648 1.8× 671 1.9× 100 1.3× 145 2.3× 90 1.6× 81 976

Countries citing papers authored by R. Descourt

Since Specialization
Citations

This map shows the geographic impact of R. Descourt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Descourt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Descourt more than expected).

Fields of papers citing papers by R. Descourt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Descourt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Descourt. The network helps show where R. Descourt may publish in the future.

Co-authorship network of co-authors of R. Descourt

This figure shows the co-authorship network connecting the top 25 collaborators of R. Descourt. A scholar is included among the top collaborators of R. Descourt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Descourt. R. Descourt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Greillier, Laurent, Florian Guisier, Catherine Daniel, et al.. (2025). Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study. Lung Cancer. 209. 108766–108766.
2.
Mennecier, B., Jonathan Khalifa, R. Descourt, et al.. (2024). Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study. BMC Cancer. 24(1). 421–421. 2 indexed citations
3.
Mok, Tony, Geoffrey Liu, Alexis B. Cortot, et al.. (2023). 585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib. Annals of Oncology. 34. S1698–S1699. 1 indexed citations
4.
Jamme, Philippe, Jean‐Baptiste Assié, Rémi Veillon, et al.. (2023). Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study. Targeted Oncology. 18(4). 585–591. 3 indexed citations
5.
Mezquita, Laura, Ernest Nadal, Santiago Ponce Aix, et al.. (2023). 1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor. Annals of Oncology. 34. S849–S850. 1 indexed citations
6.
Ricordel, Charles, R. Corre, François Lucia, et al.. (2023). Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). Translational Lung Cancer Research. 12(2). 266–276. 3 indexed citations
7.
8.
Guisier, Florian, R. Descourt, L. Falchero, et al.. (2022). Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study). Clinical Lung Cancer. 23(8). e545–e549. 6 indexed citations
9.
10.
11.
Baldacci, Simon, Benjamin Besse, Virginie Avrillon, et al.. (2020). 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S843–S843. 1 indexed citations
12.
13.
Geier, Margaux, R. Descourt, R. Corre, et al.. (2018). MA08.10 Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases. Journal of Thoracic Oncology. 13(10). S384–S385. 10 indexed citations
14.
15.
Descourt, R., et al.. (2018). False Positive 18F-FDG Positron Emission Tomography Findings in Schwannoma—A Caution for Reporting Physicians. Frontiers in Medicine. 5. 275–275. 9 indexed citations
16.
Guibert, Nicolas, Fabrice Barlési, R. Descourt, et al.. (2017). OA10.06 Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study). Journal of Thoracic Oncology. 12(1). S283–S283. 1 indexed citations
17.
Quéré, Gilles, R. Descourt, G. Robinet, et al.. (2016). Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer. BMC Cancer. 16(1). 210–210. 26 indexed citations
18.
Leroyer, Christophe, et al.. (2012). Delayed noninvasive reduction of large bullae following thoracic irradiation. Clinical Imaging. 36(5). 609–611. 2 indexed citations
19.
Tromeur, Cécile, et al.. (2011). Un cas de tumeur carcinoïde typique diagnostiqué sur un « syndrome du lobe supérieur ». Revue des Maladies Respiratoires. 28(9). 1172–1175. 2 indexed citations
20.
Descourt, R., Marc Righini, Marc Carrier, & Grégoire Le Gal. (2008). Place du cancer parmi les facteurs de risque de la maladie thromboembolique veineuse. Pathologie Biologie. 56(4). 178–183. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ofer Rotem Breakdown of academic impact, for papers by Angélique Da Silva Breakdown of academic impact, for papers by Takatoshi Fujishita Breakdown of academic impact, for papers by Farastuk Bozorgmehr Breakdown of academic impact, for papers by Laurence Venat‐Bouvet Breakdown of academic impact, for papers by Anne‐Flore Plane Breakdown of academic impact, for papers by Xiaobo He Breakdown of academic impact, for papers by Atsuto Mouri Breakdown of academic impact, for papers by Marie Florescu Breakdown of academic impact, for papers by Shota Omori
Rankless by CCL
2026